Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report

This case report details the first known instance of successful rapid hair regrowth in a 50-year-old female patient with alopecia universalis (AU) after treatment with deucravacitinib, a selective TYK2 inhibitor. The patient, who also had psoriasis and hypothyroidism, had previously failed multiple treatments including topical minoxidil, corticosteroids, and cyclosporine. After switching to deucravacitinib in April 2023, she experienced significant hair regrowth on her eyebrows, eyelashes, body, and scalp within 6 weeks. This outcome suggests that deucravacitinib may be a promising treatment for AU, warranting further investigation into its efficacy for alopecia areata and other interferon-mediated dermatoses.